Introduction
Patients with unilateral germ cell cancer of the testis have an increased risk ofdeveloping a tumour in the contralateral testis. The magnitude of this risk has been reported to be between 1% and 2%. 2 These cancers are probably always preceded by carcinoma in situ.34 On the other hand, carcinoma in situ in the contralateral testis has been found in roughly 5% of patients at the time of treatment for the initial testicular cancer.5
The spontaneous course of carcinoma in situ in the contralateral testis is unknown and may be influenced by the treatment given for the initial cancer. It has therefore been our policy not to perform a contralateral orchidectomy or employ other therapeutic interventions for carcinoma in situ unless invasive growth becomes apparent during follow up. We describe the course of carcinoma in situ of the contralateral testis detected in 27 patients during screening of 500 patients with unilateral testicular germ cell cancer.
Patients and methods
During July 1972 to January 1985, 500 patients with unilateral testicular germ cell cancer were examined for carcinoma in situ of the contralateral testis. In the first six years only one surgical department participated in the screening project, and in this period only 13 biopsy specimens were examined. Thereafter an increasing number of surgical departments participated, and since 1980 a biopsy specimen from the contralateral testis has 2) .
Results
Of the 500 patients screened, 27 (5 4%) had carcinoma in situ of the contralateral testis. Table I gives selected clinical data for these 27 patients. Characteristics such as age, histological tumour type, and distribution of staging were similar to those of patients with testicular cancer in general. 7 During follow up six patients developed a contralateral testicular cancer seven to 45 months after the diagnosis of carcinoma in situ, whereas one patient had early invasive growth of undifferentiated germ cell cancer adjacent to the changes of carcinoma in situ in the initial biopsy specimen. Table II gives the details of the initial and contralateral tumours. Diagnosis of contralateral testicular cancer was based on routine biopsy in three cases, detection of tumour by ultrasound in three, and growth of the testis in the remaining case. All patients were classified as having stage I disease at the time of the second orchidectomy and received no further treatment ( The only treatment in these cases was irradiation of the regional para-aortic and pelvic lymph nodes, whereas the remaining testis was carefully shielded. The scattered radiation dose to the testis was 0 3-0 8 Gy (30-80 rads).
The spontaneous course of carcinoma in situ in the contralateral testis is illustrated in a life table" (fig 3) based on data from the 19 patients who received no systemic treatment and from two further patients who were included up to the time that they received systemic treatment for disseminated relapse of the initial cancer. The estimated risks of developing invasive cancer within three and five years were 40% and 50%, respectively.
In the group of patients not given systemic treatment carcinoma in situ was detected repeatedly in all follow up biopsy samples, save for the first one in two patients. In both these cases the changes of carcinoma in situ were seen again in the next follow up biopsy sample a year later. Thus spontaneous disappearance of carcinoma in situ was not observed.
Eight patients with carcinoma in situ in the contralateral testis received 
Discussion
This study has elucidated the spontaneous course of carcinoma in situ in the contralateral testis of patients with unilateral testicular germ cell cancer. The estimated risk for untreated carcinoma in situ to progress to invasive cancer was 40% within three years and 50% within five years. A similar risk has been estimated for carcinoma in situ in the testes of infertile men. 4 The estimate was based on data from patients receiving irradiation ofthe regional lymph nodes or no additional treatment after the initial orchidectomy. The scattered radiation dose to the testis of less than 0-8 Gy (80 rads) in the former group was, in this respect, considered insignificant.
Our data strongly support the concept that testicular germ cell tumours are preceded by carcinoma in situ. Thus patients with carcinoma in situ of the testis had a high risk of developing an invasive tumour, whereas none of the patients without carcinoma in situ in the screening biopsy sample developed a contralateral cancer. The concept also accords with the fact that carcinoma in situ is nearly always present in the tissue adjacent to testicular germ cell tumours. '4 i5 Spontaneous disappearance of carcinoma in situ did not occur in our series. Nevertheless, we still do not know whether carcinoma in situ invariably progresses to invasive growth. Some cases may persist in a premalignant state, which may help to explain the difference between the high incidence of carcinoma in situ (5 4%) and the presumed incidence of bilateral testicular cancer (1-2%). The influence of chemotherapy on the course of carcinoma in situ may be another explanation for this apparent discrepancy. Finally, the previous reported incidence of bilateral testicular cancer may have been underestimated.
Combination chemotherapy with cisplatin, vinblastine, and bleomycin appears to eradicate carcinoma in situ. Nevertheless, a longer follow up period will be needed to show whether this effect is permanent. It should be noted that development of a contralateral cancer has occasionally been observed despite prior combination chemotherapy including regimens containing cisplatin, vinblastine, and bleomycin.'5 Furthermore, we have unpublished data on four patients who developed contralateral testicular cancer after having received bleomycin and vincristine simultaneously with irradiation.
These patients were treated according to an early protocol of the Danish testicular carcinoma study for non-seminoma stage 1,9 before establishment of the screening procedure for carcinoma in situ in the contralateral testis. Thus, though we have no information about changes of carcinoma in situ-before treatment of these four patients, this chemotherapeutic regimen is probably not enough to eradicate carcinoma in situ of the testis. On the other hand, intensive chemotherapy with all three agents is too toxic for the treatment of premalignant disease. Hence chemotherapy should be given only in accordance with the classification of the initial testicular cancer and not for carcinoma in situ of the contralateral testis. None of our patients died as a result of progression of the carcinoma in situ. All patients developing cancer ofthe contralateral testis appeared to have been cured by Qrchidectomy alone. One patient developed metastases in supraclavicular lymph nodes 15 months after the second orchidectomy but it was impossible to determine whether this was relapse related to the initial or to the second testicular cancer.
It appears that patients receiving chemotherapy for the initial testicular cancer have a minimal risk of developing a contralateral tumour. These patients should be offered continuous clinical observation, including follow up biopsies, without any further treatment. Patients with carcinoma in situ not receiving chemotherapy have a high risk of developing a contralateral cancer. For these patients it is important to devise an effective and at the same time acceptable treatment for the changes of carcinoma in situ in order to avoid a second orchidectomy and subsequent androgen insufficiency. We are investigating the efficacy of localised irradiation of the testis, and our preliminary results show that a dose of 20 Gy (2000 rads) given over 10 days may eradicate carcinoma in situ of the testis without appreciably affecting Leydig cell function.'
In conclusion, our findings show the importance of performing a biopsy ofthe contralateral testis in patients with testicular cancer. If the biopsy specimen is without carcinoma in situ the patient may be assured that the risk of developing a contralateral cancer is extremely small. If carcinoma in situ is present it is possible to diagnose invasive growth at an early stage by a suitable follow up programme to eradicate the changes of carcinoma in situ-and avoid invasive growth. We-therefore recommend that-all patients with unilateral testicular germ cell cancer should be offered a contralateral testicular biopsy.
